Rory Shallis, MD
Rory Shallis, MD
Specialty: Hematology/Oncology
Program: Malignant Hematology
Language(s): English
-
Overview
Cancer Focus:
Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndromes (MDS)Dr. Shallis received his MD degree from Rutgers-Robert Wood Medical School, Piscataway, New Jersey. He completed an Internal Medicine Residency at Brown University-Rhode Island Hospital, Providence, followed by a Hematology-Oncology Fellowship at Yale University-New Haven Hospital, Connecticut. Dr. Shallis joins us from Yale University School of Medicine, where he was an Assistant Professor in the Section of Hematology, Department of Internal Medicine.
Dr. Shallis’s clinical interests focus on the care of patients with myeloid malignancies and acute leukemias, particularly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). His research interests center on clinical investigation for patients with myeloid malignancies, particularly clinical trials of novel agents and combination therapies.
-
Participating Trials
Clinical Trial 23594
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Eganelisib ()
Status: OpenClinical Trial 23602
A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: AUTX-703 ()
Status: OpenIf you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775. -
Publications
- Joshi U, Shallis RM. MECOM-Rearranged Acute Myeloid Leukemia: Pathobiology and Management Strategies. Hematol Rep. 2025 Oct.17(6). Pubmedid: 41283235. Pmcid: PMC12642003.
- Wang R, Stempel JM, Shallis RM, Huntington SF, Zeidan AM, Neparidze N, Di M, Bewersdorf JP, Mendez L, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia. 2025 Nov.2(4):100159. Pubmedid: 41216598. Pmcid: PMC12597058.
- Bewersdorf JP, Hasle V, Shallis RM, Thompson E, Lopes de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox BA, Zeidan AM. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Ther Adv Hematol. 2025 Jun.16. Pubmedid: 40546817. Pmcid: PMC12182606.
- Moseley A, LeBlanc M, Freidlin B, Shallis RM, Zeidan AM, Sallman DA, Erba HP, Little RF, Othus M. Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials. Clin Trials. 2025 Jun.22(3):361-366. Pubmedid: 39815460. Pmcid: PMC12143638.
- Getz TM, Bewersdorf JP, Kewan T, Stempel JM, Bidikian A, Shallis RM, Stahl M, Zeidan AM. Beyond HMAs: Novel Targets and Therapeutic Approaches. Semin Hematol. 2024 Dec.61(6):358-369. Pubmedid: 39389839.
- Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec.99(12):2388-2391. Pubmedid: 39253997.
-
Patient Comments
124 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments